Open AccessIn Vivo Efficacy and Pharmacokinetics of the 2-Aminomethylphenol Antimalarial JPC-3210 in the Aotus Monkey-Human Malaria Model
Author(s) -
Fiona McCallum,
Geoff W. Birrell,
Marina Chavchich,
Ivor Harris,
Nicanor Obaldía,
Karin van Breda,
Gavin D. Heffernan,
David P. Jacobus,
Dennis Shanks,
Michael D. Edstein
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01538-19
Subject(s) - plasmodium falciparum , plasmodium vivax , malaria , in vivo , pharmacokinetics , pharmacology , biology , potency , virology , in vitro , immunology , biochemistry , microbiology and biotechnology
Nonimmune Aotus monkeys infected with Plasmodium falciparum and Plasmodium vivax were cured of their infections when treated with a single oral dose of 5 mg/kg and 10 mg/kg of the 2-aminomethylphenol, JPC-3210, respectively. Corresponding mean blood elimination half-lives of JPC-3210 were lengthy at 19.1 days and 20.5 days, respectively. This in vivo potency and lengthy half-life supports the further development of JPC-3210 as a promising, long-acting blood schizontocidal antimalarial for malaria treatment and prevention.